Intraperitoneal cisplatin cytarabine treatment refractory recurrent ovarian carcinoma Preclinical evaluation impressive concentration-dependent cytotoxic synergy cisplatin cytarabine ovarian carcinoma clinical relevance observations patients refractory recurrent ovarian carcinoma phase II trial intraperitoneal IP cisplatin course cytarabine mg course Treatment days maximum monthly courses surgical reevaluation patients clinical evidence disease regimen secondary development severe thrombocytopenia courses platelets Additional toxicities abdominal pain moderate time therapy patients evidence infection bacterial peritonitis patients surgical reassessment Fourteen confidence interval CI assessable patients defined responses CI patients tumor nodules cm diameter CI patients lesion cm CI complete responses CRs patients cm disease none patients tumor nodules IP cisplatin/cytarabine results high response rate patients minimal residual ovarian carcinoma activity low patients bulky intraabdominal disease 